TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
E Baulu, C Gardet, N Chuvin, S Depil - Science Advances, 2023 - science.org
T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
CA Klebanoff, SS Chandran, BM Baker… - Nature Reviews Drug …, 2023 - nature.com
The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
C Puig-Saus, B Sennino, S Peng, CL Wang, Z Pan… - Nature, 2023 - nature.com
Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss
of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced …
of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced …
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic …
Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T
cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their …
cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their …
Clinical delivery of circular RNA: lessons learned from RNA drug development
Circular RNAs (circRNA) represent a distinct class of covalently closed-loop RNA molecules,
which play diverse roles in regulating biological processes and disease states. The …
which play diverse roles in regulating biological processes and disease states. The …
Neoantigens: promising targets for cancer therapy
Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy
Cancer immunotherapy that deploys the host's immune system to recognize and attack
tumors, is a promising strategy for cancer treatment. However, its efficacy is greatly restricted …
tumors, is a promising strategy for cancer treatment. However, its efficacy is greatly restricted …
Computational immunogenomic approaches to predict response to cancer immunotherapies
Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …
establishment of large-scale genomic collaborative efforts along with the development of …